(Q34034016)

30 July 2017

1 reference

title

Clinical application of GnRH-antagonists (English)

1 reference

30 July 2017

Felberbaum RE

1

1 reference

30 July 2017

Ludwig M

series ordinal

2

1 reference

30 July 2017

Diedrich K

series ordinal

3

1 reference

30 July 2017

publication date

1 August 2000

1 reference

Molecular and Cellular Endocrinology

30 July 2017

published in

1 reference

30 July 2017

volume

166

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

9-14

1 reference

Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix).

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

1 reference

7 January 2021

The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2800%2900291-4

7 January 2021

10.1016/S0303-7207(00)00291-4

Identifiers

DOI

1 reference

30 July 2017

1 reference